[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thromboembolic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thromboembolic-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,69,93,116,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100623851","the-correlation-of-lewis-antigens-with-vte-100623851",false,"NCT07402005","The Correlation of Lewis Antigens With VTE","Correlation of Lewis Erythrocyte Antigens With the Risk of Venous Thromboembolic Disease-VTE","Inclusion Criteria:\n\n* Adult patients aged 18-78 years with a personal history of deep venous thrombosis and\u002For Pulmonary Embolism.\n\nExclusion Criteria:1. Current pregnancy or postpartum period 2. Hepatic insufficiency 3. Alcoholic cirrhosis\n\n\\-",true,"ALL","18 Years","78 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if certain factors in a person's blood are linked to a history of venous thromboembolic disease (VTED), which includes conditions like deep vein thrombosis.\n\nLewis system antigens are natural markers found on red blood cells. Past research suggests that people without these specific markers might have a higher chance of developing heart disease, but the link to blood clots in veins is not well understood.\n\nThis study aims to answer:\n\n* Are certain Lewis antigen types more common in people with a history of VTE?\n* Do the Lewis antigen results relate to other known blood clot risk factors? Researchers will identify Lewis a and b antigens in 100 participants who attend the Haemostasis Disorders Clinic at the University Hospital of Larissa. All participants are people with a personal history of deep vein thrombosis, with or without an inherited or acquired tendency for blood clots.\n\nResearchers will also record other known risk factors for VTED for each participant. This study is self-funded.",[26],"Thromboembolic Disease",[28],"VTE, LEWIS ANTIGEN","NOT_YET_RECRUITING","2026-02-03",{"date":32,"type":33},"2026-02-11","ACTUAL",{"date":35,"type":22},"2026-01-19",{"date":37,"type":22},"2027-01-18",{"name":39,"class":40},"Larissa University Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100616208","heparins-interference-in-argatroban-measurement-100616208","NCT07302620","HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT","HIMA","Inclusion Criterias:\n\n* Adult patient (≥ 18 years)\n* Patient anticoagulated with UFH or LMWH\n* Sample sent to the Hematology Laboratory of the University Hospitals of Strasbourg (HUS) and analyzed for measurement of the anti-Xa activity of an anticoagulant in routine care\n\nExclusion Criteria:\n\n* Patient receiving an anticoagulant other than UFH or LMWH\n* Insufficient sample volume",{"count":49,"type":22},70,"Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) provide anticoagulation through their anti-Xa and anti-IIa activity. This anti-IIa activity can lead to an overestimation of argatroban's activity when switching to an anti-IIa anticoagulant such as argatroban. This situation can be critical because argatroban is generally administered following heparin therapy due to suspected heparin-induced thrombocytopenia. Therefore, there is both a significant thrombotic risk induced by the underlying condition and a hemorrhagic risk induced by the anticoagulation. For this reason, it is important to be able to accurately monitor the anti-IIa activity of argatroban. To date, the test used to determine the anti-IIa activity of argatroban at the Hematology Laboratory of the Strasbourg University Hospitals (HUS) is a modified thrombin time (with a calibration curve adapted for argatroban). When switching between several molecules with anti-IIa activity, this test does not allow for the differentiation of the anti-IIa activity attributable to each anticoagulant.\n\nThere are no data in the literature to determine whether heparins interfere with this test, and if so, its extent.",[26],[26,53,54,55,56,57],"HEPARINS","ARGATROBAN","Unfractionated heparin (UFH)","Low molecular weight heparins (LMWH)","Anti-Xa and anti-IIa activity","RECRUITING","2025-12-10",{"date":61,"type":33},"2025-12-24",{"date":63,"type":33},"2024-12-03",{"date":65,"type":22},"2026-01",{"name":67,"class":40},"University Hospital, Strasbourg, France",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":68},"100428626","the-safety-and-efficiency-of-endovascular-treatment-of-acute-or-subacute-thromboembolic-occlusions-of-lower-extremity-100428626","NCT04861506","The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Physician-initiated, Prospective, Multi-center, Observational Study: The Safety and Efficiency Result of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Inclusion criteria\n\n1. Patients aged 18 years or older.\n2. Diagnosis of acute or subacute limb ischemia classified as Rutherford classification stage I to IIb.\n3. Rutherford classification ranging from 3 to 5.\n4. Successful guidewire passage through the lesion of the femoropopliteal artery lesion, followed by further endovascular treatment. There are no restrictions will be implemented on the methods used for guidewire passage through the target lesion. The presence of thrombus must be confirmed via angiography and\u002For DSA and must be associated with occlusions of the lower extremity or ISR.\n5. Mechanical thrombectomy device (MTD) and\u002For pharmacomechanical thrombectomy (PMT) and\u002For percutaneous aspiration thrombectomy(PAT) and\u002For CDT (catheter-directed thrombolysis) performed for thrombus removal.\n6. The lower extremity artery must have a healthy runoff of at least 10 cm above the ankle with at least one healthy dorsalis pedis artery, medial plantar artery, or lateral plantar artery connecting to the digital artery below the ankle.\n7. Informed consent signed by patients.\n\nExclusion criteria\n\n1. Acute or subacute limb ischemia patients with Rutherford classification stage III.\n2. Patients diagnosed with thromboangiitis obliterans.\n3. Patients requring open surgery or hybrid operation after contrast radiography.\n4. Patients with a history of stroke, cerebral hemorrhage, gastrointestinal bleeding, myocardial infarction, or similar conditions in the past 3 months.\n5. Patients with known allergies to heparin, low molecular weight heparin, or contrast agents.\n6. Patients at high risk for bleeding.\n7. Pregnant or lactating women.\n8. Patients with other conditions that may complicate study participation or significantly reduce life expectancy (\\\u003C 2 years), such as tumors, severe liver disease, and cardiac insufficiency.\n9. Patients enrolled in other clinical studies within the past 3 months.\n10. Patients unwilling or refusing to sign the informed consent form.\n\n    \\-",{"count":77,"type":22},400,"Based on the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic occlusions of lower extremity included stage IIb were treated with endovascular procedures. Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular treatments. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.",[26,80,81,82,83],"Lower Extremity Problem","Endovascular Treatment","Safety Issues","Efficacy, Self","2025-09-12",{"date":86,"type":33},"2025-09-15",{"date":88,"type":33},"2021-04-01",{"date":90,"type":22},"2025-12-31",{"name":92,"class":40},"First People's Hospital of Hangzhou",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":68},"100491871","impact-of-remote-care-in-patients-diagnosed-with-thromboembolic-disease-of-low-risk-100491871","NCT05684770","Impact of Remote Care in Patients Diagnosed With Thromboembolic Disease of Low Risk","Evaluation of Feasibility and Impact of Remote Care in Patients With Thromboembolic Disease of Low Risk","TEVEDOM","Inclusion Criteria:\n\n* patients identified in the emergency department with a thromboembolic disease, with a deep vein thrombosis or pulmonary embolism with a low risk of mortality according to recommendations\n* affiliated or beneficiary of social protection\n\nExclusion Criteria:\n\n* patient having a severe obstruction syndrome, a thromboembolic disease already under treatment or a suspicion of thrombocytopenia induced by heparin\n* patient with an active hemorrhage or a major risk of hemorrhage, a renal severe failure, comorbidities such as cancer, or the impossibility to organise a consultation or a patient in a non favorable medico-social context\n* patient with a caval thrombosis\n* patient suffering of a disease at hemorrhagic risk or neurosurgery intervention done in the last month or other surgery in the last 15 days prior to inclusion\n* patient with contraindication of direct oral anticoagulants, such as bitherapy with antiplatelet agent, imidazoles, macrolides, antiretroviral treatments or an anti-phospholipid syndrome\n* patient that lives in an area not covered by internet\n* patient that has no primary care physician\n* patient not able to understand the study (language, psychological problem) or not able to read or write\n* patient under legal protection",{"count":102,"type":22},50,"INTERVENTIONAL",[105],"NA","The goal of this clinical trial is to learn about the feasibility and impact of remote care in patients diagnosed with thromboembolic disease of low risk. The main questions it aims to answer are:\n\n* the evaluation of feasibility of organisation between different healthcare professionals (hospital physicians, primary care physician) at 6 months and 1 year\n* the evaluation of complication rate, hospitalisation related to thromboembolic disease rate, compliance to treatment rate at 6 months and 1 year Participants will receive indication of treatment according to national recommendations. Additionnally, they will receive for the length of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.",[26],"2025-09-09",{"date":86,"type":33},{"date":111,"type":22},"2025-09",{"date":113,"type":22},"2028-03",{"name":115,"class":40},"Centre Hospitalier Eure-Seine",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":103,"phases":128,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100493900","clonal-hematopoiesis-and-nets-formation-in-venous-thrombosis-clodette-100493900","NCT05711173","Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)","Role of Clonal Hematopoiesis and NETs Formation in Unusual Venous Thrombosis (CLODETTE)","CLODETTE","Inclusion Criteria:\n\n* Patients (male or female) less than 50 y.o with :\n* Splanchnic venous territory thrombosis or\n* Cerebral venous thrombosis or\n* Venous thrombosis of the upper limb or\n* Pulmonary embolism (1st episode if male, 2nd episode if female) unprovoked or\n* 1 episode of deep vein thrombosis + 1 episode of arterial thrombosis\n\nExclusion Criteria:\n\n* Presence of a major or minor transient venous thrombosis risk factor:\n* Surgery within the last 3 months preceding the qualifying thrombotic episode\n* Lower limb fracture with immobilization \\> 3 days in the last 3 months preceding the qualifying thrombotic episode\n* Presence of estro-progestational contraception\n* Pregnancy\n* Immobilization for acute medical reasons within the last 3 months preceding the qualifying thrombotic episode\n* Air or car travel \\> 6 hours\n* Presence of a major or minor persistent risk factor for venous thrombosis:\n* Presence of active cancer (solid cancer or hematologic malignancy)\n* Chronic inflammatory digestive or joint diseases\n* Ongoing treatment with heparin (low molecular weight heparin (LMWH) or unfractionated heparin (UFH))\n* Presence of an abnormality on the thrombophilia test among the following abnormalities\n* Protein C deficiency\n* Protein S deficiency\n* Anti-thrombin deficiency\n* Heterozygous or homozygous factor II mutation\n* Heterozygous or homozygous factor V mutation\n* Presence of anti-phospholipid syndrome\n* Presence of myeloproliferative neoplasia\n* Presence of paroxysmal nocturnal hemoglobinuria","6 Years","50 Years",{"count":127,"type":22},150,[105],"Thrombo-embolic venous diseases are represented by deep venous thrombosis and\u002For pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.",[131,26,132,133],"Venous Thromboses","Neutrophil Extracellular Trap Formation","Clonal Hematopoiesis of Indeterminate Potential",[135,136,137],"Thrombosis","Venous thrombosis","Clonal hematopoiesis of indetermined potential","2025-03-20",{"date":140,"type":33},"2025-03-21",{"date":142,"type":33},"2023-03-03",{"date":144,"type":22},"2027-03",{"name":146,"class":40},"University Hospital, Bordeaux",7,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100531576","prospective-single-arm-multicenter-study-to-evaluate-the-effectiveness-and-safety-of-endovascular-treatment-in-patients-with-cerebral-aneurysms-using-p64-and-p48-flow-diverter-stents-100531576","NCT06201598","Prospective, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Endovascular Treatment in Patients With Cerebral Aneurysms Using P64 and P48 Flow-Diverter Stents","pSPAIN_HPC","Inclusion Criteria:\n\n* Patients over 18 years old with incidental, symptomatic, and\u002For ruptured cerebral aneurysms.\n* Signed informed consent by the patient or their representative.\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Absence of signed informed consent by the patient or their representative.\n* Known, medically untreatable allergy to iodinated contrast.\n* Pregnant women or those breastfeeding.",{"count":156,"type":22},100,"The use of flow-diverting stents for the endovascular treatment of cerebral aneurysms has proven to be effective and efficient in several clinical studies, leading to its widespread adoption. Devices with a higher number of filaments have a greater flow-diverting effect and less variation when there are changes in the caliber of the underlying vessel or in curved vessels. However, ischemic complications secondary to their implantation have been reported, prompting the development of various strategies to reduce their thrombogenicity. Phenox is the only company to date that has developed an anti-thrombogenic coating, known as HPC (Hydrophilic Polymer Coating), which, when applied to the p64 MW HPC and p48 MW HPC devices, has shown to reduce the likelihood of thromboembolic complications associated with their implantation.",[159,26],"Cerebral Aneurysm",[161,162,163,164,165],"Cerebral aneurysm","Flow-diverting stents","Thrombogenicity","p64 MW HPC","p48 MW HPC","2024-11-20",{"date":168,"type":33},"2024-11-22",{"date":170,"type":33},"2024-01-12",{"date":172,"type":22},"2025-12-15",{"name":174,"class":40},"Hospital Universitario Central de Asturias",11]